SEC Filing Summary: Xenomics, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Xenomics, Inc. on May 25, 2007, reporting an event that occurred on May 21, 2007. The registrant is incorporated in Florida with principal executive offices in New York, New York. Note: The input metadata referenced "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as Xenomics, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific corporate event regarding warrant terms.
Material Changes
On May 21, 2007, Xenomics, Inc. and BSI Multihevetia ("BSI") agreed to amend a warrant agreement. The amendment extends the expiration date of a warrant owned by BSI, which is exercisable for 500,000 shares of the Company's common stock. The expiration date was extended from June 21, 2007, to August 21, 2007.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the specific warrant amendment described in Item 8.01.
Investor Verification Checklist
- Verify the total number of outstanding warrants and their respective expiration dates.
- Confirm the exercise price of the 500,000 shares covered by the BSI warrant.
- Review the original warrant agreement to understand the terms under which the extension was granted.
- Check for any subsequent filings regarding the exercise or further amendment of this warrant.